This disclosure describes methods that generally include administering to an immune compromised subject an amount of a lymphotoxin &bgr receptor (LT&bgrR) agonist effective to increase immune function in the subject compared to a suitable control immune compromised subject. In some cases, the method can result decreasing the period of immune deficiency in the subject compared to a suitable control immune compromised subject.
